Psilocybin is the prodrug active compound in psilocybin mushrooms, converted in the body to psilocin. Under investigation for treatment-resistant depression, PTSD, OCD, alcohol use disorder, and other indications. Approved for therapeutic use in Australia in 2023. Remains Schedule I in the United States. Over 100 active clinical trials globally as of early 2026.